Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus REGONOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus REGONOL.
DONEPEZIL HYDROCHLORIDE vs REGONOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases involved in angiogenesis, oncogenesis, and tumor microenvironment, including VEGFR1-3, TIE2, PDGFR-β, FGFR1, KIT, RET, RAF-1, and BRAF.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
Intravenous: 400 mg every 12 hours for 60 doses. Maintenance: 400 mg twice daily for 180 days (6 months).
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Terminal half-life of 2–4 hours; clinically relevant for dosing every 6–8 hours in renal impairment.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Approximately 70% renal (unchanged) and 30% biliary/fecal as glucuronide conjugates.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor